Hepatitis C infection. Computer illustration showing liver and close-up view of hepatitis C viruses. Studies show that mortality, morbidity, and hepatic decompensation risks increase with coinfection ...

Findings showed that in patients treated with glecaprevir/pibrentasvir, the overall SVR12 rate was 96%, with 0 patients experiencing virologic failure. The Food and ...

AbbVie (NYSE: ABBV) announced today that Health Canada has approved MAVIRET (glecaprevir/pibrentasvir tablets) for the treatment of acute and chronic hepatitis C virus (HCV) infection in adults and ...

Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low ...

Millions of people in the U.S. and around the world are living with hepatitis C virus (HCV). But over the past decade, direct-acting antivirals (DAA) have proven effective against HCV, curing more ...

BUFFALO, N.Y. – Telemedicine is widely perceived as an important tool for potentially improving health care access for the underserved. However, few randomized controlled trials have been conducted to ...

Pharmacological treatment is recommended for patients with chronic HCV infection, advanced fibrosis, compensated cirrhosis, liver transplant, severe extrahepatic manifestations, HIV co-infection, or ...

Atea Pharmaceuticals has announced the initiation of the Phase 3 C-FORWARD trial, which evaluates the combination regimen of bemnifosbuvir and ruzasvir for treating hepatitis C virus (HCV). This trial ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ...